A clinical study of traditional Chinese medicine combined with western medicine in treatment of primary IgA nephropathy (IgAN) in CKD stage 3

INTERVENTION: Valsartan:oral valsartan;group combination of Chinese and Western medicine:Valsartan+Chuanhuang No.1 prescription; CONDITION: IgA nephropathy PRIMARY OUTCOME: creatine;urine protein; INCLUSION CRITERIA: 1. Selection criteria: Subjects must meet all of the following selection criteria to enter the introduction period: 1) Females or males aged = 18; 2) Renal biopsy confirms primary IgA nephropathy; 3) 24‐hour urine protein quantitative = 0.75 g, or urine protein creatinine ratio (UPCR) = 0.5 g/g; 4) 59=eGFR= 30mL/min/1.73 m2 calculated using the CKD‐EPI cooperative creatinine formula (CKD‐EPI2009); 5) Males with fertility and female subjects of childbearing age are required to use effective contraception between the time of signing the informed until the end of the trial; Female subjects of childbearing age included women who had not been menopausal and who had not been menopause for more than 2 years; Male subjects were required to agree not to donate sperm during the study period; 6) Be able to sign an informed consent form, understand and agree to comply with the requirements of the study and the trial process arrangement.